Solriamfetol - Latest Advances

Drug Interactions With Excessive Daytime Sleepiness Treatments.

Journal: The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians

Published: October 07, 2025

Potential treatments for attention-deficit/Hyperactivity disorder: a focus on phase III trials.

Journal: Expert opinion on pharmacotherapy

Published: September 23, 2025

Solriamfetol improves daily fatigue symptoms in adults with myalgic encephalomyelitis/chronic fatigue syndrome after 8 weeks of treatment.

Journal: Journal of psychopharmacology (Oxford, England)

Published: September 17, 2025

Daily solriamfetol improved performance on a memory and attention task in people with obstructive sleep apnea and excessive daytime sleepiness: a plain language summary.

Journal: Postgraduate medicine

Published: May 06, 2025

Solriamfetol for the treatment of excessive daytime sleepiness in participants with obstructive sleep apnea with different levels of adherence to primary OSA therapy: Subgroup analysis of a randomized clinical trial.

Journal: Sleep medicine

Published: April 17, 2025

Correction to: SURWEY real-world study of solriamfetol: initiation, titration, safety, efficacy, and follow-up experience for patients with obstructive sleep apnea in Germany.

Journal: Sleep & breathing = Schlaf & Atmung

Published: April 09, 2025

Expert consensus on the diagnosis and treatment of excessive daytime sleepiness in obstructive sleep apnea

Journal: Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases

Published: March 30, 2025

Management options for excessive daytime sleepiness in patients with obstructive sleep apnea.

Journal: Expert review of respiratory medicine

Published: March 19, 2025

Post-marketing safety of solriamfetol: A retrospective pharmacovigilance study based on the us food and drug administration adverse event reporting system.

Journal: PloS one

Published: March 16, 2025

Residual Excessive Daytime Sleepiness in Obstructive Sleep Apnoea and New Pharmacological Possibilities for Treatment.

Journal: Archivos de bronconeumologia

Published: March 10, 2025

Patients with obstructive sleep apnea in Germany.

Journal: Sleep & breathing = Schlaf & Atmung

Published: September 12, 2024

Comorbidity of obstructive sleep apnea and narcolepsy: A challenging diagnosis and complex management.

Journal: Sleep medicine: X

Published: June 26, 2024

Filters

Drug Interactions With Excessive Daytime Sleepiness Treatments.

Drug Interactions With Excessive Daytime Sleepiness Treatments.

Potential treatments for attention-deficit/Hyperactivity disorder: a focus on phase III trials.

Potential treatments for attention-deficit/Hyperactivity disorder: a focus on phase III trials.

Solriamfetol improves daily fatigue symptoms in adults with myalgic encephalomyelitis/chronic fatigue syndrome after 8 weeks of treatment.

Solriamfetol improves daily fatigue symptoms in adults with myalgic encephalomyelitis/chronic fatigue syndrome after 8 weeks of treatment.

Daily solriamfetol improved performance on a memory and attention task in people with obstructive sleep apnea and excessive daytime sleepiness: a plain language summary.

Daily solriamfetol improved performance on a memory and attention task in people with obstructive sleep apnea and excessive daytime sleepiness: a plain language summary.

Solriamfetol for the treatment of excessive daytime sleepiness in participants with obstructive sleep apnea with different levels of adherence to primary OSA therapy: Subgroup analysis of a randomized clinical trial.

Solriamfetol for the treatment of excessive daytime sleepiness in participants with obstructive sleep apnea with different levels of adherence to primary OSA therapy: Subgroup analysis of a randomized clinical trial.

Correction to: SURWEY real-world study of solriamfetol: initiation, titration, safety, efficacy, and follow-up experience for patients with obstructive sleep apnea in Germany.

Correction to: SURWEY real-world study of solriamfetol: initiation, titration, safety, efficacy, and follow-up experience for patients with obstructive sleep apnea in Germany.

Expert consensus on the diagnosis and treatment of excessive daytime sleepiness in obstructive sleep apnea

Expert consensus on the diagnosis and treatment of excessive daytime sleepiness in obstructive sleep apnea

Management options for excessive daytime sleepiness in patients with obstructive sleep apnea.

Management options for excessive daytime sleepiness in patients with obstructive sleep apnea.

Post-marketing safety of solriamfetol: A retrospective pharmacovigilance study based on the us food and drug administration adverse event reporting system.

Post-marketing safety of solriamfetol: A retrospective pharmacovigilance study based on the us food and drug administration adverse event reporting system.

Residual Excessive Daytime Sleepiness in Obstructive Sleep Apnoea and New Pharmacological Possibilities for Treatment.

Residual Excessive Daytime Sleepiness in Obstructive Sleep Apnoea and New Pharmacological Possibilities for Treatment.

Patients with obstructive sleep apnea in Germany.

Patients with obstructive sleep apnea in Germany.

Comorbidity of obstructive sleep apnea and narcolepsy: A challenging diagnosis and complex management.

Comorbidity of obstructive sleep apnea and narcolepsy: A challenging diagnosis and complex management.